Kodiak Sciences Inc.
KOD
Classifica tra le azioni
#3152
Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical... Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer. This compound is currently undergoing Phase IIb/III clinical trials, targeting illnesses such as wet age-related macular degeneration (AMD), diabetic macular edema, previously untreated macular edema resulting from retinal vein occlusion, and non-proliferative diabetic retinopathy. In its earlier, preclinical development pipeline, the company is also working on KSI-501, a bispecific conjugate designed for retinal conditions involving inflammation, and KSI-601, a triplet inhibitor aimed at addressing dry AMD. Established in 2009, this Palo Alto, California-based company operated under the name Oligasis, LLC before rebranding as Kodiak Sciences Inc. in September 2015.
Prezzo delle azioni
$90.83
Ultima sincronizzazione: 2026-10-19
Capitalizzazione di mercato
$5.71B
Variazione (1 giorno)
5.92%
Variazione (1 anno)
413.16%
Paese
US
Scambia Kodiak Sciences Inc. (KOD)
Categoria
Healthcare
Rapporto P/B per Kodiak Sciences Inc. (KOD)
Rapporto P/B al October 2026 TTM: 83.12
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Kodiak Sciences Inc., il rapporto P/B attuale (TTM) è 83.12. Alla fine del 2023, era pari a 0.60.
Storico del rapporto P/B per Kodiak Sciences Inc. da 2016 a 2026
Rapporto P/B alla fine di ogni anno
| Anno | Rapporto P/B | Cambia |
|---|---|---|
| 2026 (TTM) | 83.12 | 2,288.62% |
| 2024 | 3.48 | 480.70% |
| 2023 | 0.60 | -30.10% |
| 2022 | 0.86 | -35.23% |
| 2021 | 1.32 | -15.19% |
| 2020 | 1.56 | -1.01% |
| 2019 | 1.58 | 168.87% |
| 2018 | 0.59 | -174.79% |
| 2017 | -0.78 | 113.24% |
| 2016 | -0.37 | 0.00% |
Rapporto P/B per aziende simili o concorrenti
| Azienda | Rapporto P/B | Differenza del rapporto P/B | Il paese |
|---|---|---|---|
| 6.251 | -92.48% |
US
|
|
| 13.2547 | -84.05% |
US
|
|
| 4.208 | -94.94% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | -92.56% |
NL
|
